Supplementary table 1

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient No** | **Treatment** | **Best RECIST response**  | **Progression free survival (days)** | **Overall Survival (days)** | **Site of PRE biopsy** | **Days to EDT biopsy** | **Site of EDT biopsy** |
| 1 | Nivolumab | PD  | 9 | 147 | LN | 7 | Skin |
| 2 | Nivolumab | PD  | 58 | 58 | SQ | 6 | SQ |
| 3 | Pembrolizumab | PD | 96 | 258 | SQ | 1 | Spine |
| 4 | Pembrolizumab | PD | 120 | 206 | Skin | 65 | SQ |
| 5 | Nivolumab | SD | 191 | 191 | SQ | 10 | SQ |
| 6 | Pembrolizumab | non-CR/PD | 324 | 324 | SQ | 44 | SQ |
| 7 | Pembrolizumab | SD | 335 | 825 | LN | 7 | SQ |
| 8 | Pembrolizumab | CR  | 460 | 460 | Brain | 14 | SQ |
| 9 | Pembrolizumab | PR | 1174 | 1174 | SQ | 7 | SQ |
| 10 | Pembrolizumab | PR | 1189 | 1189 | SQ | 3 | LN |
| 11 | Nivolumab | CR | 1328 | 1328 | SQ | 2 | SQ |
| 12 | Pembrolizumab | PD  | 85 | 279 | Skin | 11 | Skin |
| 13 | Pembrolizumab/Placebo + CombiDT | PD | 164 | 333 | SQ | 56 | SQ |

PD = partial response, SD = stable disease, CR = complete response

LN = lymph node, SQ = Subcutaneous